Cristina Tita, MD
Advanced Heart Failure and Transplant Cardiology · Jackson, MINPI 1861605362
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,348 of the $3,698 with a category attached, or 63.5%. Abbott accounts for 77.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $1,835 and has fallen 74.9% since, to $461 in 2025.
Across 29 payments — averaging $127.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Abiomed$392
- Procyrion, Inc.$271
- Medtronic$156
- Novo Nordisk$18
Across 8 payments — averaging $47,339 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Procyrion, Inc.$219K
- E.r. Squibb & Sons, L.L.C.$150K
- Sanofi US Services Inc.$10K
What the payments were for
- Consulting fees$1,35037%
- Food & beverage$2,34863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $2,861 |
| Abiomed | 3 | $392 |
| Procyrion, Inc. | 2 | $271 |
| Medtronic | 1 | $156 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,698 in reported general payments places this provider in the 55th percentile of 27 advanced heart failure and transplant cardiology providers in Michigan.
See all advanced heart failure and transplant cardiology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndaqelTafamidis Meglumine | 12 | $234,757 |
| JardianceEmpagliflozin | 143 | $192,903 |
| EntrestoSacubitril/Valsartan | 106 | $142,717 |
| EliquisApixaban | 64 | $77,938 |
| FarxigaDapagliflozin Propanediol | 16 | $24,350 |
| XareltoRivaroxaban | 14 | $20,088 |
| Repatha SureclickEvolocumab | 13 | $19,221 |
| Sirolimus | 34 | $12,434 |
| Tacrolimus | 86 | $11,573 |
| Bumetanide | 114 | $5,969 |
| Mycophenolate Mofetil | 53 | $4,897 |
| Isosorbide Dinitrate | 27 | $3,269 |
| Eplerenone | 23 | $2,797 |
| Carvedilol | 171 | $2,768 |
| Atorvastatin Calcium | 163 | $2,666 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Jackson
- Jennifer CowgerDetroit$165K
- David FerminGrand Rapids$105K
- Michael DickinsonGrand Rapids$80K
- Thomas CascinoAnn Arbor$39K
- Sangjin LeeGrand Rapids$25K
- Matthew GonzalezGrand Rapids$22K
- Keith AaronsonAnn Arbor$22K
- Waleed Al-DarziDetroit$11K
- Abbas BitarAnn Arbor$8K
- Gillian GraftonDetroit$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.